Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2SCLC, Extensive Stage 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 30Nivolumab 15Paclitaxel 13Cyclophosphamide 12Carboplatin 12sacituzumab govitecan 8Cisplatin 8Capecitabine 7130-nm albumin-bound paclitaxel 7Gemcitabine 6fludarabine 5durvalumab 5avelumab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Biopsy 5camrelizumab 4Specimen Handling 4Interleukin-2 4Injections 4Immune Checkpoint Inhibitors 4Docetaxel 4toripalimab 3talazoparib 3Leucovorin 3Everolimus 3Clinical Trials, Phase II as Topic 3Bevacizumab 3yeast-CEA vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Triple Negative Breast Neoplasms × fluzoparib × Clear all
NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Fudan University

Phase 1/2 Unknown
125 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown
140 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡